| Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis NICE TA289 | Ruxolitinib | Not recommended | 26 Jun 2013 | Replaced by TA386 |
| Dapagliflozin in combination therapy for treating type 2 diabetes NICE TA288 | Dapagliflozin | Recommended Only in research | 26 Jun 2013 Updated 23 Nov 2016 | Current |
| Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism NICE TA287 | Rivaroxaban | Recommended | 26 Jun 2013 | Current |
| Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) NICE TA286 | — | Terminated (no company submission) | 22 May 2013 | Current |
| Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer NICE TA285 | Bevacizumab | Not recommended | 22 May 2013 | Current |
| Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer NICE TA284 | Bevacizumab | Not recommended | 22 May 2013 | Current |
| Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion NICE TA283 | Ranibizumab | Recommended Optimised | 22 May 2013 Updated 20 May 2024 | Current |
| Pirfenidone for treating idiopathic pulmonary fibrosis NICE TA282 | Pirfenidone | Optimised | 24 Apr 2013 | Current |
| Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) NICE TA281 | — | Terminated (no company submission) | 24 Apr 2013 | Current |
| Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs NICE TA280 | Abatacept | Optimised | 24 Apr 2013 | Replaced by TA375 |
| Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures NICE TA279 | — | Recommended | 24 Apr 2013 | Current |
| Omalizumab for treating severe persistent allergic asthma NICE TA278 | Omalizumab | Recommended | 24 Apr 2013 | Current |
| Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) NICE TA277 | — | Terminated (no company submission) | 27 Mar 2013 | Current |
| Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis NICE TA276 | Colistimethate Sodium, Tobramycin | Optimised Recommended | 27 Mar 2013 | Current |
| Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation NICE TA275 | Apixaban | Recommended | 27 Feb 2013 Updated 2 Jul 2021 | Current |
| Ranibizumab for treating diabetic macular oedema NICE TA274 | Ranibizumab | Optimised | 27 Feb 2013 Updated 26 Oct 2023 | Current |
| Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) NICE TA273 | Tadalafil | Terminated (no company submission) | 23 Jan 2013 | Current |
| Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract NICE TA272 | Vinflunine | Not recommended | 23 Jan 2013 | Current |
| Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy NICE TA271 | — | Not recommended | 23 Jan 2013 | Replaced by TA301 |
| Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) NICE TA270 | Decitabine | Terminated (no company submission) | 12 Dec 2012 | Current |
| Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma NICE TA269 | Vemurafenib | Recommended | 12 Dec 2012 Updated 1 Jan 2015 | Current |
| Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma NICE TA268 | Ipilimumab | Recommended | 12 Dec 2012 | Current |
| Ivabradine for treating chronic heart failure NICE TA267 | Ivabradine | Recommended | 28 Nov 2012 | Current |
| Mannitol dry powder for inhalation for treating cystic fibrosis NICE TA266 | — | Optimised | 28 Nov 2012 | Current |
| Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours NICE TA265 | Denosumab | Recommended Not recommended | 24 Oct 2012 | Current |
| Alteplase for treating acute ischaemic stroke NICE TA264 | Alteplase | Recommended | 26 Sep 2012 | Current |
| Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer NICE TA263 | Bevacizumab | Not recommended | 22 Aug 2012 | Current |
| Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) NICE TA262 | Adalimumab | Terminated (no company submission) | 25 Jul 2012 | Replaced by TA329 |
| Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism NICE TA261 | Rivaroxaban | Recommended | 25 Jul 2012 | Current |
| Botulinum toxin type A for the prevention of headaches in adults with chronic migraine NICE TA260 | Botulinum toxin type A | Recommended | 27 Jun 2012 | Current |
| Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen NICE TA259 | Abiraterone acetate | Recommended | 27 Jun 2012 Updated 27 Jul 2016 | Current |
| Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer NICE TA258 | Erlotinib | Recommended | 27 Jun 2012 | Current |
| Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 NICE TA257 | Lapatinib, Trastuzumab | Not recommended | 27 Jun 2012 | Current |
| Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation NICE TA256 | Rivaroxaban | Recommended | 23 May 2012 Updated 2 Jul 2021 | Current |
| Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen NICE TA255 | Cabazitaxel | Not recommended | 11 May 2012 | Replaced by TA391 |
| Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis NICE TA254 | Fingolimod | Recommended | 25 Apr 2012 | Current |
| Boceprevir for the treatment of genotype 1 chronic hepatitis C NICE TA253 | — | Recommended | 25 Apr 2012 | Withdrawn |
| Telaprevir for the treatment of genotype 1 chronic hepatitis C NICE TA252 | — | Recommended | 25 Apr 2012 | Withdrawn |
| Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia NICE TA251 | Imatinib, Nilotinib, Dasatinib | Recommended Not recommended | 25 Apr 2012 | Current |
| Eribulin for the treatment of locally advanced or metastatic breast cancer NICE TA250 | Eribulin | Not recommended | 3 Apr 2012 | Replaced by TA423 |
| Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation NICE TA249 | Dabigatran Etexilate | Recommended | 15 Mar 2012 Updated 2 Jul 2021 | Current |
| Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes NICE TA248 | Exenatide | Recommended | 22 Feb 2012 | Current |
| Tocilizumab for the treatment of rheumatoid arthritis NICE TA247 | Tocilizumab | Recommended | 22 Feb 2012 | Current |
| Pharmalgen for the treatment of bee and wasp venom allergy NICE TA246 | — | Recommended | 22 Feb 2012 | Withdrawn |
| Apixaban for preventing venous thromboembolism after hip or knee replacement surgery NICE TA245 | Apixaban | Recommended | 25 Jan 2012 | Current |
| Roflumilast for the management of severe chronic obstructive pulmonary disease NICE TA244 | Roflumilast | Only in research | 25 Jan 2012 | Current |
| Rituximab for the first-line treatment of stage III-IV follicular lymphoma NICE TA243 | Rituximab | Recommended | 25 Jan 2012 | Current |
| Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy NICE TA242 | Cetuximab, Bevacizumab, Panitumumab | Not recommended | 25 Jan 2012 | Current |
| Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance NICE TA241 | Nilotinib, Dasatinib | Recommended Not recommended | 13 Jan 2012 | Current |
| Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) NICE TA240 | Panitumumab | Terminated (no company submission) | 14 Dec 2011 | Current |
| Fulvestrant for the treatment of locally advanced or metastatic breast cancer NICE TA239 | Fulvestrant | Not recommended | 14 Dec 2011 | Current |
| Tocilizumab for the treatment of systemic juvenile idiopathic arthritis NICE TA238 | Tocilizumab | Recommended Not recommended | 14 Dec 2011 | Current |
| Ranibizumab for the treatment of diabetic macular oedema NICE TA237 | Ranibizumab | Not recommended | 30 Nov 2011 | Replaced by TA274 |
| Ticagrelor for the treatment of acute coronary syndromes NICE TA236 | Ticagrelor | Recommended | 26 Oct 2011 | Current |
| Mifamurtide for the treatment of osteosarcoma NICE TA235 | Mifamurtide | Recommended | 26 Oct 2011 | Current |
| Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs NICE TA234 | Abatacept | Not recommended | 24 Aug 2011 | Replaced by TA280 |
| Golimumab for the treatment of ankylosing spondylitis NICE TA233 | Golimumab | Recommended | 24 Aug 2011 | Replaced by TA383 |
| Retigabine for the adjunctive treatment of partial onset seizures in epilepsy NICE TA232 | — | Recommended | 27 Jul 2011 | Current |
| Agomelatine for the treatment of major depressive episodes (terminated appraisal) NICE TA231 | — | Terminated (no company submission) | 27 Jul 2011 | Current |
| Bivalirudin for the treatment of ST-segment-elevation myocardial infarction NICE TA230 | Bivalirudin | Recommended | 27 Jul 2011 | Current |
| Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion NICE TA229 | Dexamethasone | Recommended Optimised | 27 Jul 2011 | Current |
| Bortezomib and thalidomide for the first‑line treatment of multiple myeloma NICE TA228 | Thalidomide, Bortezomib | Recommended Optimised | 27 Jul 2011 | Current |
| Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer NICE TA227 | Erlotinib | Not recommended | 29 Jun 2011 | Current |
| Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma NICE TA226 | Rituximab | Recommended | 22 Jun 2011 | Current |
| Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs NICE TA225 | Golimumab | Optimised | 22 Jun 2011 | Current |
| Golimumab for the treatment of methotrexate-naive rheumatoid arthritis (terminated appraisal) NICE TA224 | Golimumab | Terminated (no company submission) | 22 Jun 2011 | Replaced by TA375 |
| Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease NICE TA223 | Cilostazol, Pentoxifylline | Recommended Not recommended | 25 May 2011 | Current |
| Trabectedin for the treatment of relapsed ovarian cancer NICE TA222 | Trabectedin | Not recommended | 27 Apr 2011 | Replaced by TA389 |
| Romiplostim for the treatment of chronic immune thrombocytopenia NICE TA221 | Romiplostim | Recommended | 27 Apr 2011 Updated 26 Oct 2018 | Current |
| Golimumab for the treatment of psoriatic arthritis NICE TA220 | Golimumab | Recommended | 27 Apr 2011 | Current |
| Everolimus for the second-line treatment of advanced renal cell carcinoma NICE TA219 | Everolimus | Not recommended | 19 Apr 2011 | Replaced by TA432 |
| Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia NICE TA218 | Azacitidine | Recommended | 23 Mar 2011 | Current |
| Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease NICE TA217 | Donepezil, Galantamine, Memantine | Recommended Optimised | 23 Mar 2011 Updated 20 Jun 2018 | Current |
| Bendamustine for the first-line treatment of chronic lymphocytic leukaemia NICE TA216 | Bendamustine | Recommended | 23 Feb 2011 | Current |
| Pazopanib for the first-line treatment of advanced renal cell carcinoma NICE TA215 | Pazopanib | Recommended | 23 Feb 2011 Updated 1 Aug 2013 | Current |
| Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer NICE TA214 | Bevacizumab | Not recommended | 23 Feb 2011 | Current |
| Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years NICE TA213 | Aripiprazole | Recommended | 26 Jan 2011 | Current |
| Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer NICE TA212 | Bevacizumab | Not recommended | 15 Dec 2010 | Current |
| Prucalopride for the treatment of chronic constipation in women NICE TA211 | Prucalopride | Recommended | 15 Dec 2010 | Current |
| Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events NICE TA210 | Clopidogrel, Dipyridamole | Recommended Optimised | 15 Dec 2010 | Current |
| Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours NICE TA209 | Imatinib | Not recommended | 24 Nov 2010 | Current |
| Trastuzumab for the treatment of HER2-positive metastatic gastric cancer NICE TA208 | Trastuzumab | Optimised | 24 Nov 2010 | Current |
| Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) NICE TA207 | Temsirolimus | Terminated (no company submission) | 27 Oct 2010 | Current |
| Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) NICE TA206 | Bendamustine | Terminated (no company submission) | 27 Oct 2010 | Current |
| Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura NICE TA205 | Eltrombopag | Not recommended | 27 Oct 2010 | Current |
| Denosumab for the prevention of osteoporotic fractures in postmenopausal women NICE TA204 | Denosumab | Optimised | 27 Oct 2010 | Current |
| Liraglutide for the treatment of type 2 diabetes mellitus NICE TA203 | Liraglutide | Recommended Optimised Not recommended | 27 Oct 2010 Updated 1 Dec 2014 | Current |
| Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab NICE TA202 | Ofatumumab | Not recommended | 27 Oct 2010 | Withdrawn |
| Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 NICE TA201 | Omalizumab | Not recommended | 27 Oct 2010 | Replaced by TA278 |
| Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C NICE TA200 | — | Recommended | 22 Sep 2010 | Current |
| Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis NICE TA199 | Etanercept, Infliximab, Adalimumab | Recommended | 25 Aug 2010 | Current |
| Tocilizumab for the treatment of rheumatoid arthritis NICE TA198 | Tocilizumab | Optimised | 25 Aug 2010 | Replaced by TA247 |
| Dronedarone for the treatment of non-permanent atrial fibrillation NICE TA197 | — | Optimised | 25 Aug 2010 Updated 1 Dec 2012 | Current |
| Imatinib for the adjuvant treatment of gastrointestinal stromal tumours NICE TA196 | Imatinib | Not recommended | 25 Aug 2010 | Replaced by TA326 |
| Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor NICE TA195 | Adalimumab, Etanercept, Infliximab, Rituximab, Abatacept | Optimised Recommended | 25 Aug 2010 | Current |
| Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) NICE TA194 | Denosumab | Terminated (no company submission) | 28 Jul 2010 | Current |
| Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia NICE TA193 | Rituximab | Optimised Only in research | 28 Jul 2010 | Current |
| Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer NICE TA192 | Gefitinib | Recommended | 28 Jul 2010 | Current |
| Capecitabine for the treatment of advanced gastric cancer NICE TA191 | Capecitabine | Recommended | 28 Jul 2010 | Current |
| Pemetrexed for the maintenance treatment of non-small-cell lung cancer NICE TA190 | Pemetrexed | Recommended | 23 Jun 2010 Updated 10 Aug 2017 | Current |
